Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System
News | Antiplatelet and Anticoagulation Therapies
Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.
News | AHA
AHA 2022 Trending Topics: Clinical Trials, Scientific Studies and AI

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

Home November 14, 2022
Home
Investigators Compared AFib Patients Treated with Catheter Ablation to Those Treated with Anti-arrhythmic Drugs Only
News | Atrial Fibrillation
Study Finds Catheter Ablation Significantly Lowers Risk of Dementia in Patients with Atrial Fibrillation

November 10, 2022 —  Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home November 10, 2022
Home
When the SARS-CoV-2 protein Nsp6 is made in a fruit fly heart (center), the heart has structural defects compared to a normal heart without the viral protein (left). When fruit fly hearts with the viral Nsp6 protein are given the metabolism changing drug 2DG (right), the hearts begin to look more normal than the ones with the viral protein that do not have the drug. Image courtesy of Zhe Han at UMSOM
News | Coronavirus (COVID-19)
How a SARS-CoV-2 Virus Protein Damages the Heart

November 10, 2022 —  Researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Precision Disease ...

Home November 10, 2022
Home
Findings from the BEST-CLI trial presented at the American Heart Association Scientific Sessions (AHA2022) indicate optimal treatment for patients with limb-threatening ischemia.  
News | AHA
BEST-CLI Clinical Trial Focuses on Optimal Treatment for Limb-Threatening Ischemia

November 10, 2022 ­– Significant findings from the clinical trial, known as “BEST-CLI — Best Endovascular versus Best ...

Home November 10, 2022
Home
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge
News | Heart Failure
New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 —  Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

Home November 09, 2022
Home
Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge
News | Hypertension
CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

Home November 09, 2022
Home
New genomic therapies for cardiovascular disease are reaching the clinical trial stage, according to moderators of a session presented at the American Heart Association Annual Scientific Session (AHA2022).
News | AHA
Progress Reported on Clinical Trials of Genomic Profiling for Cardiovascular Disease at AHA 2022

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be ...

Home November 08, 2022
Home
Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz
News | AHA
TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

Home November 08, 2022
Home
Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis
News | AHA
Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

Home November 08, 2022
Home
Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio suite of products across a range of clinical applications
News | AHA
Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm’s Product Portfolio Presented at American Heart Association ’22

November 8, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

Home November 08, 2022
Home
Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment
News | AHA
Late-Breaking Data Demonstrate AHA/ACC Guideline-Directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing

November 7, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results ...

Home November 07, 2022
Home
A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio XT provided high value from a health economic perspective
News | AHA
New Research Confirms that Zio by iRhythm Provides High Value From a Health Economic Perspective

November 7, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

Home November 07, 2022
Home
Petr Ostadal, M.D., Ph.D., Professor of Medicine, Department of Cardiology, Na Homolce Hospital, Czech Republic. Image copyright Na Homolce Hospital
News | AHA
Early Use of ECMO devices Did Not Improve Outcomes in People With Cardiogenic Shock

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...

Home November 07, 2022
Home
Study Advances Efforts to Launch CARDIALYTICS Suite of Analytic Tools
News | EP Lab
CathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm

Nov. 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions to enhance ...

Home November 05, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now